Genedata Partner Symposium 2025
March 31–April 1, 2025 | Boston, MA, USA
The annual Genedata Partner Symposium is a unique interdisciplinary event at the interface between biopharma R&D and IT. Presentations and discussions will focus on innovative applications and new industry requirements: novel molecular formats (e.g., multispecifics, TCRs, CARs, AAVs, RNA vaccines), advanced screening technologies, MS-based multi-attribute methods (MAM), NGS, molecular patient profiling, and automation and data FAIRification in biopharmaceutical R&D.
At this invitation-only event, leading biopharma companies will show how groups have set up, operate, and use Genedata solutions to transform their biotherapeutics research & development and how this results in increased efficiency and throughput. The symposium brings together people working in all areas of biopharma:
- Discovery—Screening, selection, engineering, and validation
- Development—Characterization, optimization, and cell-line engineering
- Production—Bioprocessing, biosafety, and QC
- Precision Medicine—Patient profiling and integrative (pre-)clinical research
- IT—Infrastructure, networking, and integration
- Automation—Laboratory, data and research process automation
Are You a Genedata Customer? Secure Your Spot for the Genedata Partner Symposium 2026.
Hear from Genedata Customers
Genmab
Sanofi
Novartis
Astellas
Boehringer Ingelheim
AstraZeneca
Johnson & Johnson
Merck
Zoetis
Abbvie
Bicycle Therapeutics
Treeline Biosciences
Gilead
Pfizer
2025 Highlights
Genedata Symposium Awards 2025
The Genedata Symposium Awards recognized innovation projects driving exciting advances in biopharma R&D. The winners are:
Science Winner
Genmab — Harmonizing and Streamlining Chromatography Workflows
Rik Rademaker, Ph.D., Director Cell and Molecular Sciences, Genmab
Automation Winner
Novartis — Accelerating Multi Attribute Method by LC-MS Workflows
Thomas Pohl, Ph.D., Director Analytical Characterization, Novartis
AI/ML Winner
Sanofi — Towards an Integrated Wet Lab and Dry Lab
Yves Fomekong Nanfack, Ph.D., Executive Director, Head of End-to-End AI Foundations, Large Molecules Research Platform, Sanofi
Newly Launched Genedata Chromatics Wins Bio-IT World Award
We’re thrilled to be awarded the prestigious Bio-IT Innovative Practices Award for the development of Genedata Chromatics, a unique vendor-agnostic software platform for managing and analyzing chromatography data across studies.
Launched at the Partner Symposium, the platform was developed in collaboration with Genmab, a global leader in next-generation therapeutic antibody development.
Register Your Interest for 2026
Having trouble with the form? Please try a different browser or contact us by email at symposium(at)genedata.com.
Agenda 2025
| Day 1 — Monday, March 31, 2025 | |||||||
| Plenary Session | |||||||
| 8:30–9:00 | Registration & Welcome Coffee | ||||||
| 9:00–9:10 | Opening Remarks Kurt Zingler, Managing Director USA, Genedata, San Francisco, CA, USA Wen Clifford, Head of Biologics UK, Genedata, Cambridge, UK | ||||||
| 9:10–9:30 | Automation & AI — Transforming Biopharma R&D Jana Hersch, Head of Corporate Scientific Engagement, Genedata, Lexington, MA, USA | ||||||
| 9:30–10:00 | Towards an Integrated Wet Lab and Dry Lab: Leveraging Genedata Yves Fomekong Nanfack, Executive Director, Head of E2E AI Foundations, Sanofi, Cambridge, MA, USA | ||||||
| 10:00–10:30 | Leveraging Genedata Expressionist to Accelerate Multi Attribute Method by LC-MS Workflows Thomas Pohl, Director Analytical Characterization, Novartis, Basel, Switzerland | ||||||
| 10:30–11:00 | Break | ||||||
| 11:00–11:30 | Harmonizing and Streamlining Chromatography Workflows with Chromatics Rik Rademaker, Director Cell and Molecular Sciences, Genmab, Utrecht, The Netherlands | ||||||
| 11:30–12:00 | Advancing Safety in Manufactured Human Cell Products: The Strategic Value of Next-Generation Sequencing Marco De Cecco, Director of Cytogenomics, Astellas, Westborough, MA, USA | ||||||
| 12:00–12:30 | AbbVie’s Digital Transformation: Leveraging Genedata in Biopharma Sukru Kaymakcalan, Director of Information Research and Technology Solutions, AbbVie, Worcester, MA, USA | ||||||
| 12:30–2:00 | Lunch | ||||||
| Breakout Sessions | |||||||
| Biotherapeutics Discovery & Development | Assay Analysis & Management | Mass-Spec Data Analysis | Precision Medicine | NGS-Based Development & Biosafety | |||
| 2:00–2:30 | Enabling Data Science for Macromolecular Drug Discovery Joel Bard, Associate Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA | Leveraging Genedata Screener for Cell Panel Screening Solution Ilya Papok, Senior Business Analyst, AstraZeneca, Waltham, MA, USA | Enabling BioPharma's Next Era: Agility, Automation, and Advanced Analytics in Expressionist 2025.1 and Beyond Aude Tartière, Head of Expressionist US, Genedata, San Francisco, CA, USA | Deep Learning Models for Pathology Images Guoqiang Zhang, Director of Translational Bioinformatics, Astellas, Cambridge, MA, USA Daniella Patton, Scientific Account Manager, Genedata, Lexington, MA, USA | Democratizing Bioinformatics Analysis Using Genedata Selector Playbooks | ||
| 2:30–3:00 | Product Engineering at J&J: Combinatorial Variations and Systematic Registration Peter Buckley, Associate Scientific Director, Johnson & Johnson, Spring House, PA, USA | Assay Performance Monitoring: An Arvinas Case Study Bassem Shebl, Research Investigator, Arvinas, New Haven, CT, USA | Sample Directed Automation of Peptide Mapping Data Analysis Michael E. Pettit, Principal Scientist, Characterization & Analytical Development, Biologics, Johnson & Johnson, Malvern, PA, USA | An Integrated View of Preclinical Safety & Efficacy Data on ADCs Benjamin Clauss, Scientific Account Manager, Genedata, Lexington, MA, USA | Development of Adventitious Virus Detection Assay by High-Throughput Sequencing | ||
| 3:00–3:30 | Lessons Learned from a Global Genedata Deployment: Impact on Automation, Novel Modalities, and AI/ML Kannan Sankar, Bioinformatics Scientist, Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, USA | Use of Genedata Screener for the Analysis of Screening and Selectivity Data for Small Molecule Modulators of Splicing Michel Farchi Guiraldelli, Principal Scientist, Lab Lead, Pfizer, Groton, CT, USA | Sequence Variant Identification via Bottom-Up Sequencing Michael McKinnon, Senior Scientist II, Novartis, Cambridge, MA, USA | From Data to Insight: Automated Data Workflow and Powerful Visualization for Clinical Decision-Making Hareesh Chandrupatla, Director, Data Science Platforms, Revolution Medicines, Redwood City, CA, USA | Facilitating the Journey to Validated In-House NGS Workflows | ||
| 3:30–4:00 | Enhancing Biotherapeutic Data Management at Zoetis Courtney Sharp, Senior Scientist VMRD Protein Sciences, Zoetis, Kalamazoo, MI, USA | SPR Binding Data Collection for Biotherapeutic Development and AI/ML Training Alexander Shcherbakov, Scientist, Amgen, Thousand Oaks, CA, USA | Unlocking the Potential of Genedata Expressionist in High-Throughput Mass Spec Characterization to Supercharge Biologics Discovery Steven Pomerantz, Senior Principal Scientist, Johnson & Johnson, Spring House, PA, USA | Whispers: Working with AI-Agents in a GxP Validated Environment Marc Flesch, Managing Director, Genedata, Munich, Germany | Workshop: Preparing for Your Type-D FDA Meeting | ||
| 4:00–6:00 | Demo and Poster Session | ||||||
| 6:00–8:00 | Dinner | ||||||
| Day 2 — Tuesday, April 1, 2025 | |||
| Plenary Session | |||
| 8:30–9:00 | Welcome Coffee | ||
| 9:00–9:15 | Opening Remarks Wen Clifford, Head of Biologics UK, Cambridge, UK | ||
| 9:15–9:45 | AstraZeneca's Journey with Genedata: Enhancing Decision Making in Biologics Discovery Lore Florin, Senior Director Discovery Platforms, AstraZeneca, Gaithersburg, MA, USA | ||
| 9:45–10:15 | Semantics to Further Streamline Drug Development with Genedata Profiler Ismael Velasco, Director Global Data & Insights TRD, Novartis, Basel, Switzerland | ||
| 10:15–10:45 | Navigating the Digital Transformation Journey: Focus Area — Data Governance Kausheek Nandy, Director, Digital Transformation — Research, Boehringer Ingelheim, Ridgefield, CT, USA Julia Frei, Principal Scientist I, Boehringer Ingelheim, Vienna, Austria | ||
| 10:45–11:15 | Genedata @GSK: Metadata Strategies for Molecule and Projects Insights Przemyslaw Stasica, Scientific Leader, Data Sciences — Large Molecule Discovery, GSK, Stevenage, UK Thil Batuwangala, Director, Data Sciences — Large Molecule Discovery, GSK, Stevenage, UK | ||
| 11:15–11:45 | Break | ||
| 11:45–12:30 | Panel Discussion — Data-Centric Automation in Biopharma R&D Eva Bric-Furlong, Automation Specialist, Sanofi, Cambridge, MA, USA Kate Hardy, Senior Director, Informatics and Technology, MOMA Therapeutics, Cambridge, MA, USA Joel Bard, Research Fellow, BioMedicine Design, Pfizer, Cambridge, MA, USA Michael E. Pettit, Principal Scientist, Characterization, Analytical Development, Biologics, Johnson & Johnson, Malvern, PA, USA | ||
| 12:30–2:00 | Lunch | ||
| Breakout Sessions | |||
| Biotherapeutics Discovery & Development | Assay Analysis & Management | Mass-Spec Data Analysis | |
| 2:00–2:30 | Biologics Discovery and Engineering at AbbVie Enabled by Genedata Biologics Debra Touw, Principal Scientist, Digital Strategy and Automation, AbbVie, Worcester, MA, USA | Image Analysis with Machine Learning (AI) at Arvinas, Our Journey to Genedata Debra Nickischer, Senior IT Capabilities Manager, Arvinas, New Haven, CT, USA | Critical Quality Attribute Monitoring During Biosimilars Development |
| 2:30–3:00 | Integrating Data Science Strategy in Biotherapeutics Discovery: Gilead’s Journey Ying Huang, Director of Data Science, Gilead, Foster City, CA, USA | Avoiding Annotation Anarchy: Streamlining External Ontology Management for Assay Catalog John Russo, Data Engineer, Treeline Biosciences, San Diego, CA, USA Adrienne Neal, Principal Data Program Manager, Treeline Biosciences, San Diego, CA, USA | Chemical Liability Screening for Biotherapeutic Proteins — Using a Proteomic Approach and HT Data Analysis to Identify Antibody Chemical Liabilities in Early-Stage Discovery |
| 3:00–3:30 | Break | ||
| 3:30–4:00 | PEPP in Action: High-Throughput Protein Expression and Purification at Sanofi Powered by Genedata Eva Bric-Furlong, Automation Specialist, Sanofi, Cambridge, MA, USA | A Multiplexed RF-QTOF MS & Genedata Platform for Covalent Ligand Discovery | |
| 4:00–4:30 | Implementing Genedata Biologics at Dragonfly Therapeutics: Advancing Natural Killer Based Therapies Chris Morgan, Director, Dragonfly Therapeutics, Waltham, MA, USA | From Screening to Selection: Leveraging Screener 2025 for Comprehensive Large Molecule Drug Discovery Matthias Fassler, Product Manager Genedata Screener, Genedata, Basel, Switzerland | Real-Time Monitoring of Batch and Perfusion Process Using In-Line Biocapacitance Measurements |
| 4:30–5:00 | Roadmap Genedata Biologics & Genedata Bioprocess Christoph Freiberg, Head of Science, Genedata, Basel, Switzerland | Mapping Peptides with Precision | |
| End of Symposium | |||